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Abstract
Aim: To compare survival and incident cardiovascular disease between normotensive, untreated hypertensive, treated and
poorly-controlled hypertensive and treated and well-controlled hypertensive adults.
Methods and Results: Data from the British Regional Heart Study (men) and British Women’s Heart and Health Study
(women) were used (N = 6476). Blood pressure and treatment were assessed at baseline (1998–2001) when participants
were aged 60–79 years and participants were followed up for a median of 8 years. Date and cause of death were obtained
from death certificates and non-fatal cardiovascular disease events were obtained from repeat detailed medical record
reviews. Of the whole cohort 52% of women and 49% of men had untreated hypertension and a further 22% and 18%,
respectively, had poorly treated hypertension. Just 3% of women and 4% of men had treated and well controlled
hypertension and 23% and 29%, respectively, were normotensive. Compared to normotensive individuals, incident
cardiovascular disease (fatal and non-fatal) was increased in those with poorly-controlled hypertension (Hazard Ratio (HR):
1.88; 95%CI: 1.53, 2.30), those with untreated hypertension (HR 1.46; 95%CI 1.22, 1.75) and those who were well-controlled
hypertension (HR 1.38; 95%CI 0.94, 2.03). Adjustment for baseline differences in mean blood pressure between the groups
resulted in attenuation of the increased risk in the poorly-controlled (1.52 (1.18, 1.97) and untreated groups (1.21 (0.97, 1.52),
but did not change the association in the well-controlled group. All-cause mortality was also increased in all three
hypertension groups but estimates were imprecise with wide confidence intervals.
Conclusions: Half of women and men aged 60–79 in Britain had untreated hypertension and only a very small proportion of
those with diagnosed and treated hypertension were well controlled. Those with hypertension, irrespective of whether this
was treated and controlled or not, were at greater risk of future cardiovascular disease than those who are normotensive.
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Introduction
Hypertension and high blood pressure are a major contribution
to premature mortality, disease burden and reduced quality of life
[1,2]. High blood pressure and hypertension were responsible for
7.6 million premature deaths and 92 million disability-adjusted life
years (DALYs) globally in the year 2001 [2]. Tobacco use, which
has a much higher priority for prevention and control, was
responsible for 5 million premature deaths in the year 2000 [3].
A large number of randomised controlled trials in different
populations have shown that treatment with antihypertensives
reduces the risk of all-cause mortality and fatal and non-fatal
coronary heart disease (CHD) and stroke, with the magnitudes of
these associations being proportional to the extent of blood
pressure reduction achieved by treatment [4–6]. The effects seen
in these trials also reflect the magnitudes of associations of blood
pressure with these outcomes in observational epidemiological
studies [1]. This might suggest that good control of blood pressure
with treatment in those who are hypertensive would see their risk
of future cardiovascular disease (CVD) eventually return to that of
normotensive individuals. However, in routine primary care,
where adherence to treatment and control of blood pressure is
likely to be poorer than in trials, how risk compares between
normotensives, hypertensives who are treated and well controlled,
treated but poorly controlled and untreated is unclear.
One previous study has compared survival in treated and well-
controlled hypertensives to that in normotensives [7]. In that study
all-cause and CVD mortality over 20 years follow up were greater
in 686 hypertensive men who were regularly seen, treated and
well-controlled compared to 6810 normotensive men. However,
that study was conducted in the 1970s amongst men who were all
attending a secondary care outpatient clinic and results may not be
generalisable to a contemporary population managed in primary
care, where most treatment of hypertension takes place.
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The aim of this study is to compare all-cause and cardiovascular
mortality and incident cardiovascular disease between normoten-
sive, untreated hypertensive, treated poorly-controlled hyperten-
sive (here after referred to as poorly-controlled) and treated and
well-controlled hypertensive (referred to as well-controlled) older
adults.
Methods
Ethics Statement
UK local and multi-centre medical research ethics committee’
approvals were obtained for both studies and participants gave
written informed consent for review of their medical records and
data collected as part of this study to be used.
Study participants
Data from two prospective cohort studies - the British Regional
Heart Study (BRHS) and the British Women’s Heart and Health
Study (BWHHS) – collected between 1998 and 2001 using similar
protocols were used [8]. The data from BRHS that were used
were from 4252 men who were aged 60–79 at the time of baseline
assessment of blood pressure used in this study. This data
collection represented the 20 year follow-up of survivors in BRHS,
which originally comprised 7,735 men who were recruited in
1978–1980 [9]. We only used the data from this 20 year follow-up
here for two reasons. First, at this follow-up the BWHHS was
initiated and used identical protocols to that used for the BRHS,
and therefore we were able to use data on a cohort of older women
and men (as opposed only to one of men). Second, less detailed
information on hypertensive treatment were available at the
original baseline assessment of BRHS participants in 1978–80 and
we were interested in how more contemporary antihypertensive
treatment options might be associated with survival. For example,
ACE-inhibitors were not in widespread use in the 1970s and early
80 s. The BWHHS [10] comprises 4,286 women aged 60–79, who
were selected from the same population as the BRHS and first
recruited at the time of the re-examination of the BRHS men (i.e.
1998–2001). Both studies used the same design and clinic protocol.
After excluding those with pre-existing CHD and stroke at
baseline, 3425 women and 3051 men were eligible for inclusion in
analyses.
Assessment of hypertension
For all participants blood pressure and blood pressure treatment
were assessed in clinics that took place between 1998 and 2001
when participants were aged 60–79 years. A Dinamap 1846SX
vital sign monitor was used to measure blood pressure with
correction for systematic over-estimation [11]. Measurements
were taken twice in succession with a one-minute interval, with the
participant seated, rested and their arm supported at chest level.
The mean of the two measurements was used in all analyses.
At the research nurse interview, all participants brought their
current medications and gave details of their drug history which
were coded to the British National Formulary (BNF) [12].
Assessment of mortality and CVD events
All participants in both cohort studies have been flagged with
the National Health Service Central Register (NHSCR) which
provided data on death certificates for participants who died up to
31st December 2007 for BWHHS and 1st June 2007 for BRHS.
CVD mortality was defined as an underlying cause of death coded
with any of the following international disease code 10 (ICD10)
codes: I200–259 (ischeamic heart disease), I516 (cardiovascular
disease unspecified), I600–679 (cerebrovascular disease), I690–699
(sequelae of cerebrovascular disease), G450–453 (cranial nerve
disorders) or G460–469 (polyneuropathies and other disorders of
the peripheral nervous system). Non-fatal CVD events were
obtained from medical record reviews that systematically collected
information on diagnosed myocardial infarction, angina and
stroke every two years.
Assessment of cardiovascular risk factors
Participants attended the assessment clinic having fasted for a
minimum of 8 hours. Participants were instructed to take all
medication as normal during this fast and that drinking water was
acceptable; those with insulin controlled diabetes were instructed
not to fast. Plasma glucose was measured by a glucose oxidase
Trinder method [13] using a Hitachi Modular analyser (Hitachi,
Kobe, Japan). Serum insulin was measured using an ELISA assay
which does not cross react with proinsulin [14]. High density
lipoprotein cholesterol (HDL-c) and triglyceride levels were
measured using a Hitachi 747 automated analyser (Hitachi,
Tokyo, Japan) and reagents supplied by Roche Diagnostics (Basel,
Switzerland). Low density lipoprotein cholesterol (LDL-c) was
estimated using the Friedwald equation (LDL-c = total cholesterol
minus (HDL-c+triglycerides*0.45)) [15]. Standard procedures
were used to measure height and weight as previously described
[8]. Information on smoking and physical activity was obtained
from the baseline questionnaires and research nurse interviews.
Childhood and adult social class, based on self-report of fathers
and own occupation (for women, substituted with their spouses
occupation if own is missing), were classified according to the
registrar general (of Britain) classification [16].
Definitions of hypertension
Participants were categorised on the basis of their baseline blood
pressure assessment and antihypertensive treatment into one of
four mutually exclusive groups:
1. Normotensive - systolic blood pressure ,140 mmHg and
diastolic blood pressure ,90 mmHg and not on antihyperten-
sive medication;
2. Untreated hypertensive - systolic blood pressure $140 mmHg
or diastolic blood pressure $90 mmHg and not on antihyper-
tensive medication;
3. Treated and poorly-controlled hypertensive - systolic blood
pressure $140 mmHg or diastolic blood pressure $90 mmHg
and on antihypertensive medication;
4. Treated and well-controlled hypertensive - systolic blood
pressure ,140 mmHg and diastolic blood pressure
,90 mmHg and on antihypertensive medication.
Statistical methods
Data were analysed using Cox proportional hazards regression
models, with participants’ age as the time axis and the date of the
baseline assessment (1998–2001) as the start of follow-up for each
participant. Contributions to risk were censored at the earlier of: (i)
date of death; (ii) date of emigration outside of Britain; (iii) 1st June
2007 and (iv) date of non-fatal CVD event (for the analyses with
incidence of non-fatal CVD as the outcome only). Multivariable
analyses were adjusted for differences in baseline cardiovascular
disease risk factors (body mass index, fasting insulin, glucose and
lipids, smoking, physical activity, childhood and adulthood social
class) to determine whether these explained any differences in
survival between the groups. Fasting glucose, insulin and
triglyceride levels were positively skewed and therefore geometric
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means and 95% confidence intervals are presented for these
variables in descriptive analyses and their logged values were used
in regression models. Initially, all analyses were conducted
separately for women (BWHHS) and men (BRHS). There was
no evidence of difference in associations between women and men
(all gender interaction p-values.0.1) and therefore analyses used
combined data and adjusted for gender. Proportionality assump-
tions of the Cox models were assessed using Schoenfeld residuals,
which showed no evidence of any departure from proportional
hazards in the analysis of observed data with no missing
covariables.
Of the 3425 eligible women 243 (7%) had missing blood
pressure and a further 726 (21%) had missing data on at least one
covariable; equivalent numbers for men were 9 (0.3%) and 702
(23%); outcome data were available for all participants. The
amount of missing data for any single covariable was small (,10%
in all covariables except childhood social class in women (12%
missing)). To explore whether missing data might have resulted in
selection bias we completed two sets of analyses: one including the
4797 participants (2456 women) with complete data on exposure
and all covariables, and one including all eligible participants
(6476; 3425 women) with missing exposure or covariable data
imputed. We used multiple multivariate imputation, using all
variables included in any analyses, the censoring indicator and the
log of survival time for Cox models, to impute missing values for
those variables with some missing data [17]. We carried out 20
cycles of regression switching and generated 20 imputation
datasets separately for men and women. All analyses were
conducted using Stata version 11 (Stata corporation, Texas 2005).
Results
Of the 3182 women with information on blood pressure and
treatment, 1641 (52%) had untreated hypertension, 696 (22%) had
poorly-controlled hypertension, 101 (3%) well-controlled hyper-
tension and 744 (23%) had normal blood pressure (as noted above
243 (7%) women had missing blood pressure or treatment data).
The distribution of blood pressure categories for all 3425 eligible
women, including those for whom blood pressure was imputed
when it was missing was similar: 54% with untreated hypertension,
20% with poorly-controlled hypertension, 3% with well-controlled
hypertension and 23% normotensive. Of the 3042 men 1497
(49%) had untreated hypertension, 545 (18%) had poorly-
controlled hypertension, 113 (4%) well-controlled hypertension
and 887 (29%) had normal blood pressure (9 (0.3%) had missing
blood pressure or treatment data). Thus, for both genders in over
80% of those on treatment, blood pressure was poorly-controlled.
Among the 3425 women, there were 409 deaths over a median
follow-up time of 7.6 years, giving a mortality rate of 16.3/1000
person-years. This includes 70 deaths due to cardiovascular
disease, giving a cardiovascular mortality rate of 2.8/1000 person-
years. A further 325 women experienced a non-fatal cardiovas-
cular disease event, giving a total rate of fatal or non-fatal
cardiovascular disease of 16.8/1000 person-years. Among the
3051 men, there were 585 deaths over a median follow-up time of
8.1 years, giving a mortality rate of 25.3/1000 person-years. This
includes 95 deaths due to cardiovascular disease, giving a
cardiovascular mortality rate of 4.1/1000 person-years. A further
484 men experienced a non-fatal cardiovascular disease event,
giving a total rate of fatal or non-fatal cardiovascular disease of
27.2/1000 person-years.
Table 1 shows baseline characteristics by hypertensive group in
women and Table 2 the equivalent characteristics in men. In these
tables only the 3182 women and 3042 men with complete data on
blood pressure and antihypertensive treatment are included. Both
women and men with hypertension (irrespective of treatment or
control) were older, had larger BMI, higher fasting glucose, insulin
and triglycerides than those who were classified as normotensive.
Fasting HDLc levels were slightly lower in women and men in the
well-controlled categories than other categories. Poorly-controlled
hypertensives were more likely to report never taking regular
exercise for both women and men, though differences across
categories were slight for women. In both women and men those
with normal blood pressure were more likely to be current smokers
than those in any of the hypertensive categories. Neither childhood
nor adult social class were related to hypertensive group in men,
and childhood social class was not associated with hypertensive
group in women. Women with either untreated or poorly-
controlled hypertension were more likely to be from manual
social classes in adulthood. As anticipated given the definitions of
the groups mean systolic and diastolic blood pressure were highest
in those with untreated hypertension and those with treated but
poorly-controlled hypertension and lowest in the normotensive
and well-controlled group in both genders.
Table 3 shows all-cause mortality by hypertensive group. The
results based on participants with complete data only and those
with all eligible participants (with imputed data) were generally
similar. The risk of death for all participants with hypertension
(irrespective of whether treated and, if so, whether well controlled)
was greater than normotensive individuals. Risk seemed to be
highest for those who were treated and well controlled, but the
numbers in this category were small and there was no statistical
evidence that the hazard ratio differed for any of the three
subgroups of individuals with hypertension (p-values for differ-
ences in coefficients derived from 1000 bootstrap replications to
estimate standard errors of differences between log hazard all
.0.3). Adjustment for covariables (second model) or additional
adjustment for differences in mean blood pressure across the
categories (third model) did not markedly alter the associations.
Table 4 shows cardiovascular mortality by hypertensive group.
Results were similar for the complete dataset analysis and the
imputed dataset analysis. Participants with hypertension, irrespec-
tive of treatment or whether controlled, had around double the
risk of cardiovascular mortality over the follow-up period with no
evidence that this increased risk differed by whether the patient
was treated or not or whether they were well-controlled (if treated)
or not (p-values for differences in coefficients derived from 1000
bootstrap replications to estimate standard errors of differences
between log hazard all .0.5). Adjustment for potential covariables
did not importantly alter these associations (second model).
However, additional adjustment for baseline differences between
the groups in systolic and diastolic blood pressure (third model)
attenuated the increased risk in untreated and poorly treated
hypertensives compared with normotensives towards the null,
whereas the increased risk of cardiovascular mortality in the
treated and well controlled group remained largely unchanged.
Table 5 shows all cardiovascular events (fatal plus non-fatal) by
hypertensive group in women and men combined. These results
were generally consistent with those for CVD mortality, with the
exception that in model 3 (adjustment for baseline differences in
systolic and diastolic blood pressure) the attenuation in those who
were poorly treated was somewhat less marked than in the
analyses with fatal outcomes only.
In men only we had information on duration of antihyperten-
sive treatment (shown in Table 2). In the men we therefore
examined the association between duration of treatment and
outcomes. With adjustment for all potential confounding factors
(equivalent to Model 2 in previous tables) the hazard ratio of all-
Blood Pressure Treatment and Survival
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cause mortality for each additional year of treatment was 1.01
(95%CI: 0.98, 1.04) and that for cardiovascular disease (fatal and
non-fatal combined) was 1.00 (95% CI 0.97, 1.03) indicating no
impact of duration of treatment. Additional adjustment for
baseline blood pressure (equivalent to model 3) did not change
either of these results.
Despite a large sample size (6476) and 8 years of follow-up we
found that we had limited statistical power to determine whether
those who are well controlled on treatment had similar risks to
those who were normotensive at baseline; largely due to the very
small proportion who were treated and well-controlled. The
sample size that would be required to demonstrate non-inferior
survival compared to the normotensive group (i.e. a return in those
with well controlled hypertension to similar levels as those who
were normotensive) is over 40,000 participants. This is based on
calculations assuming the same ratio of normotensives to well
controlled hypertensives and the same incidence of CVD for
normotensives as in our study, a maximum clinically irrelevant
hazard ratio of 1.1, and Type I and Type II errors of 10%.
Discussion
It is notable that in this cohort of 60–79 year British men and
women, who were initially examined between 1998 and 2001,
around half were found to have untreated hypertension. A further
25% of women and 22% of men were being treated for
hypertension but the majority of these (over 80% in both genders)
were poorly controlled (ie. .140/90 mmHg). Using the British
Hypertension Society treatment targets, (#140/85 mmHg) the
proportion who were well controlled on treatment decreased
slightly from 113 (3.7%) to 94 (3.1%) in women and from 101
(3.0%) to 96 (2.8%) in men.
Women and men with hypertension (irrespective of whether
they were on treatment or if so whether their blood pressure was
well controlled) had increased risk of all cause and CVD mortality.
With respect to CVD mortality (and to a lesser degree fatal and
non-fatal CVD), the increased risk in those with untreated
hypertension and treated but poorly controlled hypertension was
importantly influenced by differences in mean baseline blood
pressure between these groups and those who were normotensive,
with substantial attenuation to the null once this was adjusted for
in multivariable models. However, the elevated risk in the well-
controlled group compared to the normotensive group was not
explained by baseline differences in blood pressure. Our finding of
increased risk of all-cause and cardiovascular disease mortality in
those who were on treatment and well controlled is consistent with
one previous study of men only [7]. That study had considerably
greater numbers in the well treated and controlled group (and
hence greater power) than in our study since these were specifically
selected from a clinic that monitored this group regularly.
It is clear from randomised controlled trials that treatment and
good control of hypertension reduces the risk of CVD events and
increases survival compared to no treatment [4–6]. In these trials
stroke risk appears to fall within 2 or 3 years to normotensives
levels whereas only half the expected reduction on treatment is
seen for CHD risk [18]. There could be several reasons why we
find similar increased risk in those who are well-controlled to those
who are untreated and those treated but not well-controlled, and
Table 1. Baseline characteristics in British women and men aged 60–79 years without cardiovascular disease by categories of
hypertension amongst women. N= 3182.
Characteristic
Number with
complete data Mean (SD) for continuous variables or N (%) for binary variables in:
P for heterogeneity
across categories*
Normotensive Untreated HT
Treated and poorly
controlled HT
Treated and well
controlled HT
Number in each category 3182 744 1641 697 101 -
Age (years) 3182 66.3 (5.0) 68.9 (5.4) 69.8 (5.4) 66.8 (5.0) ,0.0005
Systolic BP (mmHg) 3182 124.9 (11.0) 164.7 (18.8) 169.6 (19.1) 129.0 (9.1) ,0.0005$
Diastolic BP (mmHg) 3182 69.7 (7.8) 82.7 (10.5) 84.3 (11.0) 71.7 (7.6) ,0.0005$
Body mass index (kg/m2) 3159 26.4 (4.3) 27.2 (4.7) 28.5 (5.2) 29.8 (5.1) ,0.0005$
Fasting glucose** 3055 5.7 (4.3, 7.8) 5.9 (4.2, 8.1) 6.1 (4.1, 9.2) 6.0 (3.7, 9.6) ,0.0005$
Fasting Insulin** 3086 5.9 (1.8, 19.6) 6.7 (1.9, 23.2) 7.6 (2.0, 29.2) 8.6 (1.9, 38.2) ,0.0005$
Fasting HDLc 3067 1.7 (0.4) 1.7 (0.5) 1.6 (0.4) 1.5 (0.3) ,0.0005
Fasting LDLc 3002 4.1 (1.0) 4.3 (1.1) 4.2 (1.1) 4.1 (1.1) 0.003
Fasting Triglyceride** 3073 1.5 (0.6, 3.4) 1.6 (0.7, 4.0) 1.9 (0.8, 4.6) 1.7 (0.8, 3.9) ,0.0005
Current smoker (%){ 3180 112 (15%) 186 (11%) 49 (7%) 8 (8%) ,0.0005
No regular exercise (%) 3082 23 (3%) 69 (4%) 43 (6%) 5 (5%) 0.05
Manual childhood social class (%)$${ 2828 489 (74%) 1105 (76%) 474 (77%) 75 (82%) 0.2
Manual adult social class (%)$${ 2905 202 (30%) 535 (35%) 235 (38%) 27 (30%) 0.02
On $2 blood-pressure drugs (%) N/A*** - - 218 (31%) 32 (32%) -
In this table results are only presented for those with complete data, and for those with non-missing hypertensive status; HT =Hypertensive.
*i.e. the p-value tests whether the distribution differs between any of the groups and has 3 degrees of freedom.
**For these variables geometric means and 95% confidence intervals are presented.
$Using robust standard errors to account for differences in variances between groups.
$$Manual social class defined as social class III manual/class IV/class V/armed forces.
{Included as categorical covariable with all levels (never/ex/current smoker, all levels of social class) in analysis.
***Response not required if not on drugs.
doi:10.1371/journal.pone.0017792.t001
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indeed greater risk of CVD once differences for baseline blood
pressure are taken into account. First, it is possible that
participants in the treated and well controlled group included a
substantial proportion who had only been treated for a relatively
short period of time but in men, at least, we found no evidence
that duration of treatment was associated with risk of all-cause
mortality or CVD. It is possible that dose of treatment is more
relevant that duration, or that those in the treated and well-
controlled group are adhering to their treatment more so than those
in the poorly-controlled group, but we are unable to explore this.
Second, we do not have time updated measurements of blood
pressure in this cohort and it is possible that those who were in the
well controlled group became poorly controlled over the follow-up
period. Third, it is possible that good control on treatment reflects
more aggressive treatment because these were already identified by
doctors as more at risk patients. Fourth, cardiovascular risk is multi-
factorial and here we focused on high blood pressure but adjustment
for other CVD risk factors did not have a marked impact on our
findings. Fifth, we did not have sufficient power to rule out a
clinically important treatment effect, estimating that we would need
a sample size of at least 40,000 to demonstrate (with high levels of
precision) no difference in survival or CVD between the well
controlled group and the normotensive group over 10 years of
follow-up. Lastly, it may be that for an important proportion of
those with poorly controlled hypertension, blood pressure has been
elevated for a long period prior to their initial diagnosis and then
subsequent treatment. The substantial number in our cohort with
untreated hypertension lends support to this suggestion. As a
consequence of prolonged untreated elevated blood pressure,
irreversible vascular damage may have occurred, and whilst
treatment will reduce risk compared to no treatment in this
scenario, it may be unreasonable to expect this risk to be decreased
to levels seen in those who have always been normotensive.
As our results, and those of other studies [19,20], highlight that
a substantial proportion of individuals with hypertension remain
undiagnosed and of those who are diagnosed a substantial
proportion remain untreated and/or poorly controlled, there is
still a need for better surveillance to identify, treat and monitor
those with hypertension. The baseline data for this study were
collected just prior to publication and implementation of the UK
National Service Framework [21]. They also predate the 2004 UK
New General Practitioner Contract, which specified in detail the
services to be provided in primary care and began paying practices
of achieving specified targets [22]. General practitioners meeting
the quality of clinical care required 19% of the total maximum
possible payment provided by the new contract [22]. Thus, the
introduction of this contract may have improved identification and
treatment of hypertension. A recent evaluation of this scheme
focused on just three chronic diseases – coronary heart disease,
asthma and diabetes – and did not include hypertension [23].
Study strengths and limitations
The main strength of this study is that it addresses an important
clinical question that has only been addressed previously in one
published study that only included men who were attending
secondary care clinics for treatment of their hypertension. The
Table 2. Baseline characteristics in British women and men aged 60–79 years without cardiovascular disease by categories of
hypertension amongst men. N= 3042.
Characteristic
N complete
data Mean (SD) for continuous variables or N (%) for binary variables in:
P for heterogeneity
across categories*
Normotensive Untreated HT
Treated and poorly
controlled HT
Treated and well
controlled HT
Number in each category 3042 887 1497 545 113 -
Age (years) 3042 67.0 (5.1) 68.5 (5.5) 69.3 (5.3) 68.4 (5.3) ,0.0005
Systolic BP (mmHg) 3042 124.6 (10.9) 160.9 (17.6) 165.9 (18.9) 125.9 (11.5) ,0.0005$
Diastolic BP (mmHg) 3042 77.2 (7.0) 89.9 (10.0) 91.3 (10.1) 78.8 (6.0) ,0.0005$
Body mass index (kg/m2) 3036 26.1 (3.6) 26.7 (3.5) 27.7 (3.5) 28.2 (4.2) ,0.0005$
Fasting glucose* 2906 5.6 (4.1, 7.8) 5.8 (3.9, 8.6) 6.1 (3.8, 9.8) 6.2 (3.6, 10.8) ,0.0005$
Fasting Insulin* 2895 7.4 (2.2, 24.7) 7.9 (2.3, 26.6) 9.0 (2.5, 32.7) 9.7 (2.8, 33.9) ,0.0005$
Fasting HDLc 2886 1.3 (0.2) 1.4 (0.4) 1.3 (0.3) 1.2 (0.3) ,0.0005$
Fasting LDLc 2865 3.9 (0.9) 4.0 (1.0) 3.9 (1.0) 3.9 (1.0) ,0.0005
Fasting Triglyceride* 2903 1.5 (0.6, 3.9) 1.6 (0.6, 4.1) 1.7 (0.7, 4.5) 1.8 (0.6, 4.9) ,0.0005
Current smoker (%){ 2836 183 (22%) 266 (19%) 88 (18%) 20 (19%) 0.2
No regular exercise (%) 2972 413 (48%) 717 (49%) 314 (59%) 46 (42%) ,0.0005
Manual childhood social class (%)$${ 2753 621 (78%) 1089 (80%) 401 (81%) 88 (82%) 0.5
Manual adult social class (%)$${ 3035 462 (52%) 774 (52%) 290 (53%) 57 (51%) 0.9
On $2 blood-pressure drugs (%) N/A*** - - 173 (32%) 28 (25%) -
Years on blood-pressure lowering
drugs (median (IQR))
N/A N/A N/A 6 (0,7) 3 (0,7) -
In this table results are only presented for those with complete data, and for those with non-missing hypertensive status; HT =Hypertensive.
*i.e. the p-value tests whether the distribution differs between any of the groups and has 3 degrees of freedom.
**For these variables geometric means and 95% confidence intervals are presented.
$Using robust standard errors to account for differences in variances between groups.
$$Manual social class defined as social class III manual/class IV/class V/armed forces.
{Included as categorical covariable with all levels (never/ex/current smoker, all levels of social class) in analysis.
***Response not required if not on drugs.
doi:10.1371/journal.pone.0017792.t002
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Table 3. Association of hypertension categories with all-cause mortality in women and men combined.
Hypertensive group
Total Normotensive Untreated hypertensive
Poorly treated
hypertensive Well treated hypertensive
Using subset with no missing values for any covariable/hypertensive group
N 4796 1264 2427 941 164
Deaths 635 130 339 139 27
Hazard ratios (95% CI)
Model 1* - 1 1.14 (0.93, 1.40) 1.17 (0.92, 1.49) 1.48 (0.98, 2.25)
Model 2* - 1 1.17 (0.95, 1.44) 1.22 (0.95, 1.56) 1.48 (0.97, 2.25)
Model 3* - 1 1.20 (0.92, 1.57) 1.25 (0.91, 1.72) 1.47 (0.97, 2.24)
Using imputed data for missing values (20 imputations)
N** 6476 1688 3328 1245 215
Deaths** 950 198 519 199 34
Hazard ratios (95% CI)
Model 1* - 1 1.15 (0.96, 1.36) 1.12 (0.92, 1.37) 1.26 (0.87, 1.81)
Model 2* - 1 1.19 (1.00, 1.41) 1.17 (0.95, 1.44) 1.30 (0.90, 1.88)
Model 3* - 1 1.15 (0.92, 1.44) 1.13 (0.87, 1.46) 1.28 (0.89, 1.85)
*Model 1: adjusted for sex, age (as time variable in Cox model).
Model 2: additionally adjusted for BMI, smoking, physical activity, LDL cholesterol, HDL cholesterol, triglycerides (log scale), glucose (log scale), insulin (log scale), fathers
occupational social class (childhood social class), own adult occupational social class.
Model 3: additionally adjusted for systolic and diastolic blood pressure (BP).
**Imputed numbers per group and associated numbers of events are means over 20 imputed datasets.
Numbers per group differ slightly between Tables 2, 3, 4 as time to event and the censoring variable are included as a covariable in the imputation prediction model.
doi:10.1371/journal.pone.0017792.t003
Table 4. Association of hypertension categories with CVD mortality in women and men combined.
Hypertensive group
Total Normotensive Untreated hypertensive
Poorly treated
hypertensive Well treated hypertensive
Using subset with no missing values for any covariable/hypertensive group
N 4796 1264 2427 941 164
CVD deaths 107 15 59 29 4
Hazard ratios (95% CI)
Model 1* - 1 1.60 (0.90, 2.85) 1.98 (1.05, 3.72) 1.85 (0.61, 5.58)
Model 2* - 1 1.66 (0.93, 2.96) 2.09 (1.09, 4.00) 1.70 (0.56, 5.22)
Model 3* - 1 1.09 (0.54, 2.20) 1.29 (0.58, 2.89) 1.67 (0.55, 5.12)
Using imputed data for missing values (20 imputations)
N** 6476 1688 3328 1245 215
CVD deaths** 158 21 92 39 6
Hazard ratios (95% CI)
Model 1* - 1 1.80 (1.10, 2.94) 1.97 (1.14, 3.39) 2.04 (0.82, 5.08)
Model 2* - 1 1.91 (1.17, 3.12) 2.13 (1.23, 3.71) 1.97 (0.78, 4.94)
Model 3* - 1 1.19 (0.65, 2.18) 1.26 (0.64, 2.47) 1.92 (0.77, 4.83)
*Model 1: adjusted for sex, age (as time variable in Cox model).
Model 2: additionally adjusted for BMI, smoking, physical activity, LDL cholesterol, HDL cholesterol, triglycerides (log scale), glucose (log scale), insulin (log scale), fathers
occupational social class (childhood social class), own adult occupational social class.
Model 3: additionally adjusted for systolic and diastolic blood pressure (BP).
**Imputed numbers per group and associated numbers of events are means over 20 imputed datasets.
Numbers per group differ slightly between Tables 2, 3, 4 as time to event and the censoring variable are included as a covariable in the imputation prediction model.
doi:10.1371/journal.pone.0017792.t004
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population are a random sample of women and men from across
the UK. However, we cannot assume that our results would be
generalisable to a younger population. An important limitation is
the lack of time updated information on blood pressure and
antihypertensive medication, and further study with repeat
measurements of these would be valuable. It is possible that those
who were well-controlled at baseline became less so over time and
those who were poorly controlled became more so with these two
opposite changes resulting in similar risk of outcomes in these two
groups. Thus, our findings should be interpreted as representing
differences in risk over an eight-year follow-up period amongst
groups of women and men whose hypertensive status was defined
at the start of that period only. Blood pressure was measured twice
for each participant and the mean of these two measurements
used, but both measurements were at one clinic setting and whilst
this is consistent with how hypertension is used in epidemiological
research, in clinical practice a diagnosis of hypertension would
require a second elevated measurement on a separate occasion. In
addition we have no information in this study on adherence to
prescribed treatment. We know that the participants stated that
they were taking their medication but we did not check this in any
formal way. The male participants (BRHS) in this cohort consisted
of survivors from a cohort that started 20 years prior to the
assessment that we used as baseline here. This could have resulted
in some selection (survivor) bias. However, we found no evidence
that findings in men differed from those in the BWHHS women,
who were newly recruited at the time of baseline assessment for
this study. An additional limitation is that the very small
proportion of those with hypertension who are treated and well-
controlled means that we have limited statistical power to precisely
estimate risk in this group. As is common in epidemiological
studies we used two measures of blood pressure taken at the same
clinic, whereas hypertension in clinical practice is based on repeat
measurements on different days over a three-month period. Thus,
our estimate of untreated hypertensives may overestimate what
would be found in clinical practice.
Conclusions
Whilst treatment of hypertension clearly reduces risk of CVD and
improves survival compared to no treatment [4–6], our results, and
those of one previously published study [7], suggest that individuals
in non-trial routine clinical practice with hypertension who are
treated and well-controlled remain at increased risk of all-cause
mortality and CVD compared to individuals who are normotensive.
Our results also highlight the high proportion of individuals with
untreated hypertension and the high proportion of those treated
who are poorly controlled. These findings emphasise the impor-
tance of prevention of hypertension and continued monitoring of
those on treatment with modifications to achieve good control.
Given the small proportion in our study who were well-controlled
further examination of this question in large cohort studies is
required. Large scale routine general practice data bases (e.g.
QRESEARCH database) would be capable of answering the
important question of whether survival and cardiovascular disease
risk in well-controlled hypertensives reverts to that seen in
normotensives over a reasonable follow-up period.
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Table 5. Association of hypertension categories with fatal and non-fatal CVD in women and men combined.
Hypertensive group
Total Normotensive Untreated hypertensive
Poorly treated
hypertensive Well treated hypertensive
Using subset with no missing values for any covariable/hypertensive group
N 4793 1263 2426 941 164
Events 698 142 354 180 22
Hazard ratios (95% CI)
Model 1* - 1 1.32 (1.08, 1.60) 1.77 (1.41, 2.21) 1.25 (0.80, 1.95)
Model 2* - 1 1.29 (1.06, 1.57) 1.73 (1.37, 2.18) 1.10 (0.70, 1.73)
Model 3** - 1 1.08 (0.84, 1.40) 1.42 (1.06, 1.90) 1.09 (0.69, 1.71)
Using imputed data for missing values (20 imputations)
N** 6473 1692 3322 1244 215
Events** 956 177 504 243 32
Hazard ratios (95% CI)
Model 1* - 1 1.47 (1.23, 1.75) 1.92 (1.58, 2.34) 1.47 (1.01, 2.15)
Model 2* - 1 1.46 (1.22, 1.75) 1.88 (1.53, 2.30) 1.38 (0.94, 2.03)
Model 3* - 1 1.22 (0.97, 1.52) 1.52 (1.18, 1.97) 1.38 (0.94, 2.03)
*Model 1: adjusted for sex, age (as time variable in Cox model).
Model 2: additionally adjusted for BMI, smoking, physical activity, LDL cholesterol, HDL cholesterol, triglycerides (log scale), glucose (log scale), insulin (log scale), fathers
occupational social class (childhood social class), own adult occupational social class.
Model 3: additionally adjusted for systolic and diastolic blood pressure (BP).
**Imputed numbers per group and associated numbers of events are means over 20 imputed datasets.
Numbers per group differ slightly between Tables 2, 3, 4 as time to event and the censoring variable are included as a covariable in the imputation prediction model.
doi:10.1371/journal.pone.0017792.t005
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